(Reuters) -AstraZeneca ( AZN ) reported quarterly revenue and profit above market estimates on Thursday, buoyed by resilient demand for its oncology and rare blood disorder drugs and steady growth in revenue from partnered medicines.

Its pipeline of new drugs, including blockbusters such as lung cancer drug Tagrisso, leukaemia drug Calquence and Farxiga for diabetes, coupled with resilient demand in emerging markets, have made the Anglo-Swedish firm one of the strongest performers among listed European pharmaceutical companies.

Oncology revenue grew 26% to $5.12 billion in the first quarter.

The London-listed drugmaker reported core earnings per share of $2.06 on total revenue of $12.68 billion.

Analysts were expecting a core profit of $1.92 per share on revenue of $11.84 billion, according to a company-compiled consensus.

The company stuck by its forecast of total revenue and core earnings per share to increase by percentages in the low double-digits to low-teens in 2024.

(Reporting by Eva Mathews in Bengaluru; Editing by Subhranshu Sahu)